Horizon Published (MIRROR) Trial Results of Krystexxa (pegloticase) + Methotrexate for Uncontrolled Gout in ACR Open Rheumatology
- The (MIRROR) trial evaluating Krystexxa + methotrexate (15mg/week) vs Krystexxa + PBO in a ratio (2:1) in 152 patients, showed an improvement in the patient response rate remained nearly 30 percentage points higher with methotrexate co-therapy during 12mos.
- 60.0% vs 30.8% achieved a serum urate (SU) level ≤6 mg/dL for 80% of the time, 23 percentage-point increase in the complete resolution of one tophus, 53.8% vs 31.0% had a complete resolution of one tophus with no new tophus formation and no single tophus progression. The results were consistent with 6mos. findings
- Additionally, all HAQ measures progressively decreased during treatment, greater improvement in both HAQ pain and HAQ health
Ref: Businesswire | Image: Horizon
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.